<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=ProgId content=OneNote.File>
<meta name=Generator content="Microsoft OneNote 15">
<link id=Main-File rel=Main-File href=3d169c1597044083a56412090c44abb2.htm>
<link rel=File-List href="3d169c1597044083a56412090c44abb2.files/filelist.xml">
</head>

<body lang=zh-TW style='font-family:Calibri;font-size:11.0pt'>

<div style='direction:ltr;border-width:100%'>

<div style='direction:ltr;margin-top:0in;margin-left:0in;width:6.1722in'>

<div style='direction:ltr;margin-top:0in;margin-left:0in;width:1.175in'>

<p style='margin:0in;font-family:"Calibri Light";font-size:20.0pt' lang=en-US>TRALI</p>

</div>

<div style='direction:ltr;margin-top:.0388in;margin-left:0in;width:2.3423in'>

<p style='margin:0in;font-family:Calibri;font-size:10.0pt;color:#767676'
lang=en-US>Tuesday, April 15, 2025</p>

<p style='margin:0in;font-family:Calibri;font-size:10.0pt;color:#767676'
lang=en-US>12:08 AM</p>

</div>

<div style='direction:ltr;margin-top:.4305in;margin-left:0in;width:6.1722in'>

<ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
 margin-bottom:0in'>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
     style='font-family:"Microsoft JhengHei Light";font-size:16.0pt'>編輯格式</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei Light";font-size:16.0pt'>顏色註記方式</span></li>
  <ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
   margin-bottom:0in'>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt'
       lang=zh-TW>重要標題</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt' lang=en-US> : </span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#1E4E79' lang=zh-TW>母標題藍色</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
       color:#1E4E79' lang=en-US>(</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#1E4E79' lang=zh-TW>最暗</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
       color:#1E4E79' lang=en-US>)</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#1E4E79' lang=zh-TW>標記</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt'
       lang=en-US>/</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#2E75B5' lang=zh-TW>子標題藍色</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
       color:#2E75B5' lang=en-US>(</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#2E75B5' lang=zh-TW>較暗</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
       color:#2E75B5' lang=en-US>,25%)</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#2E75B5' lang=zh-TW>標記</span></li>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt'
       lang=zh-TW>重要術式治療藥物</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt' lang=en-US> : </span><span style='font-weight:bold;
       font-family:"Microsoft JhengHei Light";font-size:11.0pt;color:#70AD47'
       lang=zh-TW>綠色標記</span><span style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#70AD47' lang=en-US>+</span><span
       style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#70AD47' lang=zh-TW>粗體</span></li>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt'
       lang=zh-TW>重要內文</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt' lang=en-US> : </span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#C00000' lang=zh-TW>紅色</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
       color:#C00000' lang=en-US>(</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#C00000' lang=zh-TW>標準色彩</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
       color:#C00000' lang=en-US>)</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt' lang=en-US>/</span><span style='font-weight:bold;
       font-family:"Microsoft JhengHei Light";font-size:11.0pt;color:#ED7D31'
       lang=zh-TW>橘色</span><span style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#ED7D31' lang=en-US>+</span><span
       style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#ED7D31' lang=zh-TW>粗體</span><span
       style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#ED7D31' lang=en-US>(</span><span
       style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#ED7D31' lang=zh-TW>橘色那一欄第一個</span><span
       style='font-weight:bold;font-family:"Microsoft JhengHei Light";
       font-size:11.0pt;color:#ED7D31' lang=en-US>)</span><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt'
       lang=en-US>(</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt' lang=zh-TW>如果同色太醜就紅橘相間</span><span style='font-family:
       "Microsoft JhengHei Light";font-size:11.0pt' lang=en-US>)</span></li>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
       style='font-family:"Microsoft JhengHei Light";font-size:11.0pt'
       lang=zh-TW>直接來複製顏色格式一定不會錯</span><span style='font-family:"Microsoft JhengHei Light";
       font-size:11.0pt' lang=en-US>xd</span></li>
  </ul>
 </ul>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
     style='font-family:"Microsoft JhengHei";font-size:16.0pt'>定義</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt'>Transfusion-Related
      Acute Lung Injury，簡稱 TRALI 是一臨床症候群，屬於非心源性肺水腫，定義為輸注含血漿的血液製品後 </span><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#C00000'>6小時內</span><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt'>，出現急性肺損傷（ALI）的症狀。特徵包括：</span></li>
  <ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
   margin-bottom:0in'>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>急性呼吸困難</span></li>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>低氧血症</span></li>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>胸部
       X 光顯示雙側肺部浸潤</span></li>
  </ul>
 </ul>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
     21pt'><span style='font-family:"Microsoft JhengHei";font-size:16.0pt'>病因</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt'>TRALI是因輸血引起的瀰漫性肺損傷所導致，其致病原因可用二次打擊模型(Two-hit
      Model) 來解釋：</span></li>
  <ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
   margin-bottom:0in'>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
       color:#C00000'>第一次打擊(Baseline)</span><span style='font-family:"Microsoft JhengHei";
       font-size:11.0pt'> : </span></li>
   <ul type=square style='direction:ltr;unicode-bidi:embed;margin-top:0in;
    margin-bottom:0in'>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>慢性酒精濫用、休克、肝臟手術、吸煙、機械通氣時較高的氣道壓力、血管內體液正平衡、低IL-10水平，以及全身性發炎。</span></li>
   </ul>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
       color:#C00000'>第二次打擊(輸血相關因素)</span></li>
   <ul type=square style='direction:ltr;unicode-bidi:embed;margin-top:0in;
    margin-bottom:0in'>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>抗白血球抗體（約80%的病例）:
        Anti-HLA class I、Anti-HLA class II以及Anti-HNA抗體</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>非抗體因素（約20%的病例)
        : 脂質介質、細胞外囊泡和老化血細胞</span></li>
   </ul>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       15pt'><span style='font-weight:bold;font-family:"Microsoft JhengHei";
       font-size:11.0pt;color:#F79646'>透過第一次打擊，使白血球聚集於肺部血管。於第二次打擊時，造成嚴重發炎反應，使肺部微血管膜通透性上升</span></li>
  </ul>
 </ul>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
     21pt'><span style='font-family:"Microsoft JhengHei";font-size:16.0pt'>診斷（2019
     Canadian Consensus Conference）</span></li>
</ul>

<div style='direction:ltr'>

<table border=1 cellpadding=0 cellspacing=0 valign=top style='direction:ltr;
 border-collapse:collapse;border-style:solid;border-color:#A3A3A3;border-width:
 1pt;margin-left:.3333in' title="" summary="">
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.0312in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:15pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt'>&nbsp;</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:4.6777in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:15pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt'>說明</p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:.9534in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:15pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt'>Type 1 TRALI</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:4.825in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <ul style='direction:ltr;unicode-bidi:embed;margin-top:0in;margin-bottom:
   0in'>
   <ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
    margin-bottom:0in'>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>輸血後6小時內急性發作</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>低血氧（PaO2/FiO2
        </span><span style='font-family:"Cambria Math";font-size:11.0pt'>≤</span><span
        style='font-family:"Microsoft JhengHei";font-size:11.0pt'>
        300或室內空氣下SpO2 &lt; 90%）</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>影像學檢查（胸部X光、CT或超音波）顯示雙側肺水腫</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
        color:#C00000'>無左心房高壓(LAH)證據(Non-cardiogenic)</span><span
        style='font-family:"Microsoft JhengHei";font-size:11.0pt'>，即使存在LAH也非低血氧的主要原因</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
        color:#C00000'>與其他ARDS風險因素無時間相關性</span></li>
   </ul>
  </ul>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:.9534in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:15pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt' lang=en-US>Type 2 </p>
  <p style='margin:0in;line-height:15pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt' lang=en-US>TRALI</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:4.7555in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <ul style='direction:ltr;unicode-bidi:embed;margin-top:0in;margin-bottom:
   0in'>
   <ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
    margin-bottom:0in'>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>符合TRALI
        type 1的前四項臨床標準</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
        color:#C00000'>存在ARDS風險因素</span><span style='font-family:"Microsoft JhengHei";
        font-size:11.0pt'>或輕度ARDS（P/F ratio : 200~300）</span></li>
    <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
        17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt'>輸血前12小時內肺部狀態穩定</span></li>
   </ul>
  </ul>
  </td>
 </tr>
</table>

</div>

<ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
 margin-bottom:0in'>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
     21pt'><span style='font-family:"Microsoft JhengHei";font-size:16.0pt'>治療</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle' lang=en-US><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt'>停止輸送可疑血品</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle' lang=en-US><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#C00000'>支持性治療，必要時使用機械通氣</span><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt'>(參考ARDS治療)，並血液動力學穩定</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle' lang=en-US><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#C00000'>不建議常規使用類固醇</span><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt'>，缺乏足夠臨床研究支持其效果</span></li>
 </ul>
</ul>

<p style='margin-left:.375in;margin-top:6pt;margin-bottom:6pt;line-height:18pt;
font-family:"Microsoft JhengHei";font-size:14.0pt' lang=en-US>&nbsp;</p>

<ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
 margin-bottom:0in'>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
     21pt'><span style='font-family:"Microsoft JhengHei";font-size:16.0pt'>預後</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#262626'>大多數患者在</span><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#C00000'>24-48小時內會改善</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
      17pt'><span style='font-family:"Microsoft JhengHei";font-size:14.0pt;
      color:#262626'>通常是自限性疾病</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
      17pt'><span style='font-family:"Microsoft JhengHei";font-size:14.0pt;
      color:#262626'>死亡率：</span></li>
  <ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
   margin-bottom:0in'>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       17pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
       color:#262626'>重症患者的存活率約53%</span></li>
   <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
       15pt'><span style='font-family:"Microsoft JhengHei";font-size:11.0pt;
       color:#262626'>相較於一般急性肺損傷患者(存活率83%)明顯較低</span></li>
  </ul>
 </ul>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
     21pt'><span style='font-family:"Microsoft JhengHei";font-size:16.0pt'>預防策略</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#262626'>使用男性或未妊娠女性的血液(懷孕使產生anti-HLA抗體機會增加)</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#262626'>使用洗滌且新鮮的血品</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle'><span
      style='font-family:"Microsoft JhengHei";font-size:14.0pt;color:#262626'>捐血者若有引起TRALI的病例應通報</span></li>
 </ul>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
     21pt'><span style='font-family:"Microsoft JhengHei";font-size:16.0pt'>與TACO(Transfusion-Associated
     Circulatory Overload)比較</span></li>
</ul>

<div style='direction:ltr'>

<table border=1 cellpadding=0 cellspacing=0 valign=top style='direction:ltr;
 border-collapse:collapse;border-style:solid;border-color:#A3A3A3;border-width:
 1pt;margin-left:.3333in' title="" summary="">
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9027in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626;text-align:center'><span style='font-weight:
  bold'>特徵</span></p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.2972in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626;text-align:center'><span style='font-weight:
  bold'>TRALI</span></p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4013in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626;text-align:center'><span style='font-weight:
  bold'>TACO</span></p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9027in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>病理機制</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.3166in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt'><span style='color:#C00000'>• 非心源性肺水腫<br>
    </span><span style='color:#262626'>• 抗體或非抗體介導的發炎反應<br>
    • 肺部微血管通透性增加</span></p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4013in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt'><span style='color:#C00000'>• 心源性肺水腫<br>
    </span><span style='color:#262626'>• 體液過量<br>
    • 左心房壓力升高</span></p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9027in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>臨床表現</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.2972in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 輸血後6小時內發生<br>
    • 雙側肺浸潤<br>
    • 無左心房高壓證據<br>
    • 可能出現發燒</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4833in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 循環負荷過重表現<br>
    • 左心衰竭表現<br>
    • 血壓可能升高</p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9222in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>CXR特徵(其實就是</p>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>non-cardiogenic vs </p>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>cardiogenic pulmonary </p>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>edema)</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.2972in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 雙側對稱性浸潤<br>
    • 正常心臟大小<br>
    • 無肺門充血<br>
    • 無胸腔積液</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4013in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 雙側浸潤<br>
    • 心臟擴大<br>
    • 肺門充血<br>
    • 可見胸腔積液<br>
    • Kerley B線</p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9027in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>治療方式</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.2972in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 支持性治療為主<br>
    • 維持氧氣供應<br>
    • 利尿劑無效</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4013in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 停止輸血<br>
    • 使用利尿劑<br>
    • 降低前負荷</p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9027in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>預防策略</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.2972in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 篩查高風險供血者<br>
    • 優先使用男性供血者血漿<br>
    • 避免多次妊娠女性血製品</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4013in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 控制輸血速度<br>
    • 監測輸血量<br>
    • 評估心功能狀態</p>
  </td>
 </tr>
 <tr>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.9027in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>預後</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:2.2972in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt;color:#262626'>• 24-48小時內可能改善<br>
    • 重症患者存活率約53%<br>
    • 通常為自限性</p>
  </td>
  <td style='border-style:solid;border-color:#A3A3A3;border-width:1pt;
  vertical-align:top;width:1.4833in;padding:2.0pt 3.0pt 2.0pt 3.0pt'>
  <p style='margin:0in;line-height:17pt;font-family:"Microsoft JhengHei";
  font-size:11.0pt'><span style='color:#262626' lang=zh-TW>• 對治療反應較好<br>
    • 及時處理預後良好<br>
    • 取決於基礎心功能</span><span lang=en-US> </span></p>
  </td>
 </tr>
</table>

</div>

<p style='margin:0in;margin-left:.375in'><img
src="TRALI_asset_0.jpg" width=480 height=320></p>

<ul type=disc style='direction:ltr;unicode-bidi:embed;margin-top:0in;
 margin-bottom:0in'>
 <li style='margin-top:0;margin-bottom:0;vertical-align:middle;margin-top:6pt;
     margin-bottom:6pt'><span style='font-family:Calibri;font-size:11.0pt'
     lang=en-US><span style='mso-spacerun:yes'> </span></span><span
     style='font-weight:bold;font-family:"Microsoft JhengHei Light";font-size:
     16.0pt' lang=zh-TW>參考資料</span></li>
 <ul type=circle style='direction:ltr;unicode-bidi:embed;margin-top:0in;
  margin-bottom:0in'>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
      17pt'><span style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
      color:#212121'>Semple JW, Rebetz J, Kapur R. Transfusion-associated
      circulatory overload and transfusion-related acute lung injury. Blood.
      2019 Apr 25;133(17):1840-1853. doi: 10.1182/blood-2018-10-860809</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
      17pt'><span style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
      color:#212121'>Tung JP, Chiaretti S, Dean MM, Sultana AJ, Reade MC, Fung
      YL. Transfusion-related acute lung injury (TRALI): Potential pathways of
      development, strategies for prevention and treatment, and future research
      directions. Blood Rev. 2022 May;53:100926. doi: 10.1016/j.blre.2021.100926</span></li>
  <li style='margin-top:0;margin-bottom:0;vertical-align:middle;line-height:
      17pt'><span style='font-family:"Microsoft JhengHei Light";font-size:11.0pt;
      color:#212121'>Goel R, Tobian AAR, Shaz BH. Noninfectious
      transfusion-associated adverse events and their mitigation strategies.
      Blood. 2019 Apr 25;133(17):1831-1839. doi: 10.1182/blood-2018-10-833988</span></li>
 </ul>
</ul>

<p style='margin:0in;font-family:Calibri;font-size:11.0pt' lang=en-US>&nbsp;</p>

</div>

</div>

</div>

<div>

<p style='margin:0in'>&nbsp;</p>

<p style='text-align:left;margin:0in;font-family:Arial;font-size:9pt;
color:#969696;direction:ltr'>使用 OneNote 建立。</p>

</div>

</body>

</html>